Endothelial activation and cytokine expression in human acute cardiac allograft rejection

• Published in: Pathology Vol. 30; no. 1; pp. 24 - 29
• Main Authors: Salom, Ruth N., Maguire, Julie A., Hancock, Wayne W.
• Format: Journal Article
• Language: English
• Published: London Elsevier B.V 01-02-1998; Informa UK Ltd; Taylor and Francis
• Subjects: allograft; Biological and medical sciences; Biopsy; Blood Coagulation Factors - analysis; cardiac; Cell Adhesion Molecules - analysis; cytokines; Cytokines - analysis; Cytokines - biosynthesis; Endothelium; Endothelium, Vascular - chemistry; Endothelium, Vascular - metabolism; Female; Graft Rejection - metabolism; Heart Transplantation - immunology; Heart Transplantation - pathology; HLA Antigens - analysis; Humans; Immunohistochemistry; Male; Medical sciences; Myocardium - chemistry; Myocardium - cytology; Myocardium - pathology; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the heart; IL; PS; vWF; MHC; allograft; Endothelium; AT-III; PC; TNF-α; XL; PDGF; mAbs; TM; cytokines; ATGAM; EMB; PECAM; EC; cardiac; Heart; Human; Immunohistochemistry; Endothelial cell; Pathogenesis; Acute; Cytokine; Cell adhesion molecule; Cardiovascular disease; Transplantation; Activation; Homotransplantation; Rejection; Pathology; Heart disease; Surgery; Graft
• ISSN: 0031-3025; 1465-3931
• DOI: 10.1080/00313029800169625

By extrapolation from the responses of cultured human umbilical vein endothelial cells (EC) and bovine aortic EC to short-term cytokine stimulation, EC activation is postulated as a likely component of the host response in acute allograft rejection and cardiac transplant-associated accelerated arteriosclerosis. To investigate the extent to which EC activation occurs in vivo in humans and to identify potential targets for therapeutic interventions, we compared the phenotypic characteristics of vascular EC as seen during clinicopathologically significant vs non-significant acute cardiac altograft rejection. We used monoclonal and monospecific polyclonat antibodies to coagulation molecules [tissue factor, thrombomodulin (TM), antithrombin 111 (AT-Ill), fibrinogen/fibrin, cross-linked fibrin and von Willebrand factor (vWF)], adhesion molecules (P-selectin, ICAM-1) and major histocompatibility complex (MHC) class I and II molecules. In addition we sought evidence of local cytokine production (IL-1, tL-2R, IL-4, IL-6, IL-7, IL-8, TNF-α, PDGFAA, PDGF-BB), which might mediate alterations in expression of these proteins. We found that in clinically significant grades of cardiac allograft rejection requiring increased immunosuppression, in contrast to lesser grades of rejection not requiring clinical intervention, there was increased microvascular EC activation and differential expression of cytokines. EC changes associated with more extensive cardiac allograft rejection requiring treatment included: (i) disruption of the normal anticoagulant state with downregulation of TM and AT-Ill, upregulation of tissue factor and vWF expression, and associated extensive fibrin deposition; (ii) upregulation of MHC class 1 antigens, which are potential targets for host cytotoxic T lymphocytes; (iii) increased expression of the leucocyte adhesion molecules P-selectin and ICAM-1; (iv) expression of the pro-inflammatory cytokines IL-lβ and TNF-α and (v) increased expression of PDGF-AA and BB, which are known to promote migration and proliferation of intimal cells, and hence may contribute to development of transplant-associated atherosclerosis. Collectively these findings suggest that immune events resulting in EC surface changes and/or production of key cytokines play a role in the pathogenesis of acute transplant rejection and may contribute to the long-term complication of accelerated arteriosclerosis in allograft coronary arteries.